COX2 genetic variation, NSAIDs, and advanced prostate cancer risk

Collective evidence suggests that cyclooxygenase 2 (COX2) plays a role in prostate cancer risk. Cyclooxygenase 2 is the major enzyme that converts arachidonic acid to prostaglandins, which are potent mediators of inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, I, Liu, X, Plummer, S J, Krumroy, L M, Casey, G, Witte, J S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Genetics and Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360347/
https://www.ncbi.nlm.nih.gov/pubmed/17609663
http://dx.doi.org/10.1038/sj.bjc.6603874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360347/
https://www.ncbi.nlm.nih.gov/pubmed/17609663
http://dx.doi.org/10.1038/sj.bjc.6603874

Ejemplares similares